Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition

Biochemical Pharmacology

Volumn 77, Issue 11, 2009, Pages 1674-1683

  Guo, Qingqu ^a   Chen, Ying ^a   Zhang, Bo ^a   Kang, Muxing ^a   Xie, Qiuping ^a   Wu, Yulian ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Emodin; Gemcitabine; Pancreatic cancer; Survivin

Indexed keywords

BETA CATENIN; EMODIN; GEMCITABINE; LYMPHOID ENHANCER FACTOR 1; SURVIVIN; TRANSCRIPTION FACTOR 7;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DIVISION; CELL MEMBRANE; CELL PROLIFERATION; CHINESE MEDICINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MITOSIS INHIBITION; MOUSE; MULTIGENE FAMILY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CASPASE 3; CELL DIVISION; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DNA PRIMERS; DRUG SYNERGISM; EMODIN; GENE EXPRESSION REGULATION; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MUSCLE, SKELETAL; PANCREATIC NEOPLASMS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPPRESSION, GENETIC;

EID: 64549101571     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.02.021     Document Type: Article

References (41)

1. Lillemoe K.D. Current management of pancreatic carcinoma. Ann Surg 221 (1995) 133-148
2. Duffy J.P., Eibl G., Reber H.A., and Hines O.J. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer 2 (2003) 12
3. Heinemann V. Gemcitabine-based combination treatment of pancreatic cancer. Semin Oncol 29 (2002) 25-35
4. Burris III H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997) 2403-2413
5. Storniolo A.M., Enas N.H., Brown C.A., Voi M., Rothenberg M.L., and Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85 (1999) 1261-1268
6. Bharti A.C., and Aggarwal B.B. Chemopreventive agents induce suppression of nuclear factor-kappaB leading to chemosensitization. Ann N Y Acad Sci 973 (2002) 392-395
7. Wang H.H., and Chung J.G. Emodin-induced inhibition of growth and DNA damage in the Helicobacter pylori. Curr Microbiol 35 (1997) 262-266
8. Chang C.H., Lin C.C., Yang J.J., Namba T., and Hattori M. Anti-inflammatory effects of emodin from ventilago leiocarpa. Am J Chin Med 24 (1996) 139-142
9. Yim H., Lee Y.H., Lee C.H., and Lee S.K. Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor. Planta Med 65 (1999) 9-13
10. Chen Y.C., Shen S.C., Lee W.R., Hsu F.L., Lin H.Y., Ko C.H., et al. Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol 64 (2002) 1713-1724
11. Jing X., Ueki N., Cheng J., Imanishi H., and Hada T. Induction of apoptosis in hepatocellular carcinoma cell lines by emodin. Jpn J Cancer Res 93 (2002) 874-882
12. Srinivas G., Anto R.J., Srinivas P., Vidhyalakshmi S., Senan V.P., and Karunagaran D. Emodin induces apoptosis of human cervical cancer cells through poly(ADP-ribose) polymerase cleavage and activation of caspase-9. Eur J Pharmacol 473 (2003) 117-125
13. Zhang L., Lau Y.K., Xi L., Hong R.L., Kim D.S., Chen C.F., et al. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene 16 (1998) 2855-2863
14. Cha T.L., Qiu L., Chen C.T., Wen Y., and Hung M.C. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res 65 (2005) 2287-2295
15. Huang Q., Shen H.M., Shui G., Wenk M.R., and Ong C.N. Emodin inhibits tumor cell adhesion through disruption of the membrane lipid Raft-associated integrin signaling pathway. Cancer Res 66 (2006) 5807-5815
16. Kim M.S., Park M.J., Kim S.J., Lee C.H., Yoo H., Shin S.H., et al. Emodin suppresses hyaluronic acid-induced MMP-9 secretion and invasion of glioma cells. Int J Oncol 27 (2005) 839-846
17. Kwak H.J., Park M.J., Park C.M., Moon S.I., Yoo D.H., Lee H.C., et al. Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer 118 (2006) 2711-2720
18. Muto A., Hori M., Sasaki Y., Saitoh A., Yasuda I., Maekawa T., et al. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther 6 (2007) 987-994
19. Shieh D.E., Chen Y.Y., Yen M.H., Chiang L.C., and Lin C.C. Emodin-induced apoptosis through p53-dependent pathway in human hepatoma cells. Life Sci 74 (2004) 2279-2290
20. Altieri D.C. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7 (2001) 542-547
21. Thomas S., and Shah G. Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt/survivin pathway. Cancer Biol Ther 4 (2005) 1226-1233
22. Gerlier D., and Thomasset N. Use of MTT colorimetric assay to measure cell activation. J Immunol Methods 94 (1986) 57-63
23. Tang Z.Y., Wu Y.L., Gao S.L., and Shen H.W. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells. J Surg Res 145 (2008) 111-123
24. Shah A.N., Summy J.M., Zhang J., Park S.I., Parikh N.U., and Gallick G.E. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 14 (2007) 3629-3637
25. Banerjee S., Zhang Y., Ali S., Bhuiyan M., Wang Z., Chiao P.J., et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 65 (2005) 9064-9072
26. Kunnumakkara A.B., Guha S., Krishnan S., Diagaradjane P., Gelovani J., and Aggarwal B.B. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67 (2007) 3853-3861
27. Cai J., Razzak A., Hering J., Saed A., Babcock T.A., Helton S., et al. Feasibility evaluation of emodin (rhubarb extract) as an inhibitor of pancreatic cancer cell proliferation in vitro. JPEN J Parenter Enteral Nutr 32 (2008) 190-196
28. Chang C.J., Ashendel C.L., Geahlen R.L., McLaughlin J.L., and Waters D.J. Oncogene signal transduction inhibitors from medicinal plants. In Vivo 10 (1996) 185-190
29. Wang L., Lin L., and Ye B. Electrochemical studies of the interaction of the anticancer herbal drug emodin with DNA. J Pharm Biomed Anal 42 (2006) 625-629
30. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
31. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3 (2003) 46-54
32. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92 (2005) 212-216
33. Zaffaroni N., Pennati M., and Daidone M.G. Survivin as a target for new anticancer interventions. J Cell Mol Med 9 (2005) 360-372
34. Liu W.S., Yan H.J., Qin R.Y., Tian R., Wang M., Jiang J.X., et al. siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity. Dig Dis Sci (2008)
35. Boon E.M., Keller J.J., Wormhoudt T.A., Giardiello F.M., Offerhaus G.J., van der Neut R., et al. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 90 (2004) 224-229
36. Lin S.Y., Xia W., Wang J.C., Kwong K.Y., Spohn B., Wen Y., et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 97 (2000) 4262-4266
37. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., et al. Identification of c-MYC as a target of the APC pathway. Science 281 (1998) 1509-1512
38. Ma H., Nguyen C., Lee K.S., and Kahn M. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 24 (2005) 3619-3631
39. Zhang T., Otevrel T., Gao Z., Ehrlich S.M., Fields J.Z., and Boman B.M. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61 (2001) 8664-8667
40. Tetsu O., and McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398 (1999) 422-426
41. Tapia J.C., Torres V.A., Rodriguez D.A., Leyton L., and Quest A.F. Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription. Proc Natl Acad Sci USA 103 (2006) 15079-15084